silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th
Company profile
Ticker
SILK
Exchange
Website
CEO
Erica Rogers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
208777622
SILK stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
28 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Silk Road Medical Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Silk Road Medical Names Chas McKhann Chief Executive Officer
2 Nov 23
8-K
Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook
10 Oct 23
8-K
Departure of Directors or Certain Officers
15 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
Transcripts
SILK
Earnings call transcript
2023 Q4
28 Feb 24
SILK
Earnings call transcript
2023 Q3
8 Nov 23
SILK
Earnings call transcript
2023 Q2
1 Aug 23
SILK
Earnings call transcript
2023 Q1
9 May 23
SILK
Earnings call transcript
2022 Q4
28 Feb 23
SILK
Earnings call transcript
2022 Q3
11 Nov 22
SILK
Earnings call transcript
2022 Q2
26 Jul 22
SILK
Earnings call transcript
2022 Q1
7 May 22
SILK
Earnings call transcript
2021 Q4
27 Feb 22
SILK
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
4
Kevin J. Ballinger
7 Mar 24
4
Lucas W. Buchanan
5 Mar 24
4
Richard Ruedy
5 Mar 24
4
Andrew S. Davis
5 Mar 24
4
Marie L. Jones
5 Mar 24
4
Chas McKhann
5 Mar 24
4
Kevin M Klemz
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.19 mm | 29.19 mm | 29.19 mm | 29.19 mm | 29.19 mm | 29.19 mm |
Cash burn (monthly) | (no burn) | 1.86 mm | 4.56 mm | 4.79 mm | 2.27 mm | 2.19 mm |
Cash used (since last report) | n/a | 11.11 mm | 27.27 mm | 28.69 mm | 13.56 mm | 13.11 mm |
Cash remaining | n/a | 18.08 mm | 1.92 mm | 498.29 k | 15.63 mm | 16.08 mm |
Runway (months of cash) | n/a | 9.7 | 0.4 | 0.1 | 6.9 | 7.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 167 |
Opened positions | 29 |
Closed positions | 37 |
Increased positions | 73 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 595.21 bn |
Total shares | 42.21 mm |
Total puts | 321.20 k |
Total calls | 540.80 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Wasatch Advisors | 5.71 mm | $85.56 bn |
Vanguard | 3.58 mm | $53.61 bn |
Capital World Investors | 2.97 mm | $44.47 bn |
BLK Blackrock | 2.92 mm | $43.79 bn |
Clearbridge Advisors | 1.73 mm | $25.87 bn |
BLVGF Bellevue | 1.43 mm | $21.44 bn |
Flynn James E | 1.40 mm | $0.00 |
STT State Street | 1.14 mm | $17.04 bn |
WP X Finance | 1.02 mm | $44.20 mm |
Marshall Wace | 977.96 k | $14.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Richard Ruedy | Common Stock | Sell | Dispose S | No | No | 17.169 | 3,800 | 65.24 k | 205,711 |
5 Mar 24 | Kevin J. Ballinger | Common Stock | Buy | Acquire P | No | No | 16.99 | 11,700 | 198.78 k | 17,807 |
5 Mar 24 | Buchanan Lucas W. | Common Stock | Sell | Dispose S | No | No | 17.169 | 9,877 | 169.58 k | 500,925 |
5 Mar 24 | Andrew S. Davis | Common Stock | Sell | Dispose S | No | No | 17.169 | 5,481 | 94.10 k | 287,773 |
5 Mar 24 | Marie L. Jones | Common Stock | Sell | Dispose S | No | No | 17.169 | 2,602 | 44.67 k | 76,894 |
1 Mar 24 | Buchanan Lucas W. | Common Stock | Grant | Acquire A | No | No | 0 | 74,954 | 0.00 | 510,802 |
1 Mar 24 | Andrew S. Davis | Common Stock | Grant | Acquire A | No | No | 0 | 62,201 | 0.00 | 293,254 |
1 Mar 24 | Marie L. Jones | Common Stock | Grant | Acquire A | No | No | 0 | 24,555 | 0.00 | 79,496 |
News
Reported Earlier, Genesis MedTech Collaborates With Silk Road Medical To Combat Stroke Risk In China With Advanced TCAR Technology
8 Mar 24
Argus Research Upgrades Silk Road Medical to Buy, Announces $24 Price Target
7 Mar 24
Breaking Down Silk Road Medical: 5 Analysts Share Their Views
29 Feb 24
Stifel Maintains Buy on Silk Road Medical, Raises Price Target to $23
29 Feb 24
JP Morgan Maintains Neutral on Silk Road Medical, Raises Price Target to $19
29 Feb 24
Press releases
Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China
7 Mar 24
Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
5 Mar 24
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
7 Feb 24